Short Interest in Fresenius SE & Co. (OTCMKTS:FSNUY) Declines By 40.6%

Fresenius SE & Co. (OTCMKTS:FSNUY) saw a large decrease in short interest in the month of July. As of July 31st, there was short interest totaling 114,842 shares, a decrease of 40.6% from the July 15th total of 193,488 shares. Based on an average daily volume of 624,752 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.0% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on FSNUY. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Fresenius SE & Co. currently has a consensus rating of “Buy”.

Fresenius SE & Co. Stock Performance

FSNUY stock opened at $13.70 on Monday. Fresenius SE & Co. has a 12 month low of $10.33 and a 12 month high of $33.93. The firm’s 50-day moving average is $12.17 and its 200 day moving average is $12.74. The company has a market capitalization of $30.86 billion, a PE ratio of 17.34 and a beta of 0.61. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.27 and a quick ratio of 0.98.

Fresenius SE & Co. (OTCMKTS:FSNUY) last issued its earnings results on Wednesday, August 5th. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $6.91 billion during the quarter, compared to the consensus estimate of $6.65 billion. Fresenius SE & Co. had a return on equity of 10.33% and a net margin of 6.67%. On average, research analysts anticipate that Fresenius SE & Co. will post 1.08 EPS for the current year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.